youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
AZN:NYSE
AstraZeneca PLC (US)
$170.08
arrow_downward
-1.15%(-1.98) 1D
$170.36
arrow_upward
+0.16% (+0.28)todayPre-market
Closed: Oct 27, 4:00:02 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AZN...
Open
$169.68
High
$171.72
Low
$169.45
Mkt. cap
262.88B
Avg. vol.
2.95M
Volume
6.02K
Dividend
1.90%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
25.43
52-wk high
$212.71
52-wk low
$80.48
EPS
$6.69
Beta
0.30
Shares outstanding
1.55B
No. of employees
96K
Open
$169.68
High
$171.72
Low
$169.45
Mkt. cap
262.88B
Avg. vol.
2.95M
Volume
6.02K
Dividend
1.90%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
25.43
52-wk high
$212.71
52-wk low
$80.48
EPS
$6.69
Beta
0.30
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
Traders Union
·
1 hour ago
AstraZeneca stock holds steady as buyer support persists around GBX12,824 support
TradingView
·
1 hour ago
AstraZeneca PLC expected to post earnings of $2.60 a share - Earnings Preview
JournalArta
·
7 hours ago
AstraZeneca Stock Analysis: Drops 0.25%, Testing Key Resistance
Investing.com South Africa
·
13 hours ago
AstraZeneca may start work on cancer vaccines, CEO says By Investing.com
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com